beacon-biosignals
(2)
David Matthews
David Matthews, PhD, is Chief Business Officer at Beacon Biosignals, the computational neurodiagnostics company turning EEG brain data into AI-powered biomarkers for neurological and psychiatric disease. A computational neuroscientist by training, he spent two decades moving between the lab, the boardroom, and the market - from NIH- and NSF-funded research at the Salk Institute to a partnership at Boston Consulting Group to commercial leadership at digital-health platform BrightInsight. He now drives partnerships and commercial growth at a company betting that the brain can be measured at home, at scale.
Jacob Donoghue
Jacob Donoghue is a physician-scientist and the co-founder and CEO of Beacon Biosignals, a Boston company applying machine learning to EEG brain data to build neurobiomarkers for psychiatric, neurological, and sleep disorders. Trained with an MD from Harvard Medical School and a PhD in neuroscience from MIT, he started Beacon in 2019 on the bet that decades of overlooked brainwave recordings could be turned into a precision-medicine engine for drug development and diagnosis. Under his leadership the company has raised over $116M, secured FDA clearance for a wearable EEG headband, acquired home sleep-testing firm CleveMed, and partnered with more than half of the world's top ten biopharma companies.